Vanderbilt study: World Trade Center responders at higher risk for blood cancer-associated mutations

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Cell donor’s socioeconomic status shapes cancer treatment outcomes

The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.

July 19, 2024

Vol.50 No.29

Drugs & Targets

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy for patients in Estonia.

May 31, 2024

Vol.50 No.22

Clinical Roundup

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.

May 24, 2024

Vol.50 No.21

Clinical Roundup

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Standard of care treatment for acute myeloid leukemia is safe and effective for adults over 80, according to a study published in Blood Neoplasia. For roughly a quarter of patients, this treatment can durably prolong survival.

May 17, 2024

Vol.50 No.20

In Brief

Ray Blind named associate director for DEI at Vanderbilt-Ingram

Ray Blind, Ingram Assistant Professor of Cancer Research, was named associate director for diversity, equity, and inclusion at Vanderbilt-Ingram Cancer Center.

April 26, 2024

Vol.50 No.17

Vanderbilt study: World Trade Center responders at higher risk for blood cancer-associated mutations

YOU MAY BE INTERESTED IN

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

Cyclophosphamide may expand transplant donor pool for patients with blood cancers

Older adults with aggressive blood cancer are responsive to treatment and show prolonged survival

Ray Blind named associate director for DEI at Vanderbilt-Ingram

Renew today!

Subscriber content

Never miss an issue!

Login